OX 1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 156-167

  Turunen, Pauli M ^a   Jäntti, Maria H ^a   Kukkonen, Jyrki P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CYTOSOLIC PHOSPHOLIPASE A2; ENDOCANNABINOID; LIPOPROTEIN LIPASE; OREXIN 1 RECEPTOR; OREXIN A; 1 (2 METHYLBENZOXAZOL 6 YL) 3 (1,5)NAPHTHYRIDIN 4 YL UREA; 1-(2-METHYLBENZOXAZOL-6-YL)-3-(1,5)NAPHTHYRIDIN-4-YL UREA; BENZOXAZOLE DERIVATIVE; DRUG DERIVATIVE; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE RECEPTOR; OREXIN RECEPTORS; UREA;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL ASSAY; CELL COMMUNICATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL STRAIN HEK293; CHO CELL; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; ARACHIDONIC ACID; BENZOXAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCANNABINOIDS; HEK293 CELLS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SIGNAL TRANSDUCTION; UREA;

EID: 84863966971     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078063     Document Type: Article

References (60)

1. Balsinde J and Balboa MA (2005) Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 17:1052-1062.
2. Baskakis C, Magrioti V, Cotton N, Stephens D, Constantinou-Kokotou V, Dennis EA, and Kokotos G (2008) Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem 51:8027-8037.
3. Bengtsson MW, Mäkelä K, Sjöblom M, Uotila S, Akerman KE, Herzig KH, and Flemström G (2007) Food-induced expression of orexin receptors in rat duodenal mucosa regulates the bicarbonate secretory response to orexin-A. Am J Physiol Gastrointest Liver Physiol 293:G501-G509.
4. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-212.
5. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
6. Bligh EG and Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917.
7. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431.
8. Crespo I, Gómez de Heras R, Rodríguez de Fonseca F, and Navarro M (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 54:219-225.
9. De Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, Marino G, and Di Marzo V (1997) Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231:82-88.
10. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, and Howlett A (1997) Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 53:255-260.
11. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
12. Di Marzo V and Petrosino S (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18:129-140.
13. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
14. 2+ influx and ERK. Biochem Biophys Res Commun 353:475-480.
15. Ellis J, Pediani JD, Canals M, Milasta S, and Milligan G (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824.
16. 2+) and comparison with the other cPLA2 isoforms. J Biol Chem 285:36100-36111.
17. 2ζ in mouse lung fibroblasts. J Biol Chem 282:11676-11686.
18. Ghosh M, Tucker DE, Burchett SA, and Leslie CC (2006) Properties of the Group IV phospholipase A2 family. Prog Lipid Res 45:487-510.
19. Glass M, Hong J, Sato TA, and Mitchell MD (2005) Misidentification of prostamides as prostaglandins. J Lipid Res 46:1364-1368.
20. Grimsey NL, Graham ES, Dragunow M, and Glass M (2010) Cannabinoid receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. Biochem Pharmacol 80:1050-1062.
21. Håkansson M, de Lecea L, Sutcliffe JG, Yanagisawa M, and Meister B (1999) Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. J Neuroendocrinol 11:653-663.
22. Hilairet S, Bouaboula M, Carrière D, Le Fur G, and Casellas P (2003) Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278:23731-23737.
23. Ho YC, Lee HJ, Tung LW, Liao YY, Fu SY, Teng SF, Liao HT, Mackie K, and Chiou LC (2011) Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J Neurosci 31:14600-14610.
24. Holmqvist T, Akerman KE, and Kukkonen JP (2002) Orexin signaling in recombinant neuron-like cells. FEBS Lett 526:11-14.
25. Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, and Kukkonen JP (2005) OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J Biol Chem 280:6570-6579.
26. Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53-79.
27. Hu J and el-Fakahany EE (1993) Role of intercellular and intracellular communication by nitric oxide in coupling of muscarinic receptors to activation of guanylate cyclase in neuronal cells. J Neurochem 61:578-585.
28. Huang H, Acuna-Goycolea C, Li Y, Cheng HM, Obrietan K, and van den Pol AN (2007) Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food in-take and cognitive arousal. J Neurosci 27:4870-4881.
29. Jäntti MH, Putula J, Somerharju P, Frohman MA, and Kukkonen JP (2012) OX1 orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol 165: 1109-1123.
30. 2+ influx. Br J Pharmacol 150:97-104.
31. 1 orexin/hypocretin receptors. Cell Mol Life Sci 65:1948-1956.
32. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, and Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380.
33. Kathuria S, Gaetani S, Fegley D, Valinõ F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
34. Kirkham TC, Williams CM, Fezza F, and Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557.
35. Kukkonen JP (2011) A ménage à trois made in heaven: G-protein-coupled receptors, lipids and TRP channels. Cell Calcium 50:9-26.
36. Kukkonen JP and Åkerman KEO (2005) Intracellular signal pathways utilized by the hypocretin/orexin receptors, in Hypocretins as Integrators of Physiological Signals (de Lecea L and Sutcliffe JG eds) pp 221-231, Springer Science+Business Media, Berlin.
37. Kukkonen JP, Holmqvist T, Ammoun S, and Akerman KE (2002) Functions of the orexinergic/hypocretinergic system. Am J Physiol Cell Physiol 283:C1567-C1591.
38. Lee MW, Kraemer FB, and Severson DL (1995) Characterization of a partially purified diacylglycerol lipase from bovine aorta. Biochim Biophys Acta 1254:311-318.
39. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
40. López M, Seoane L, García MC, Lago F, Casanueva FF, Señarís R, and Diéguez C (2000) Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus. Biochem Biophys Res Commun 269:41-45.
41. 2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem 275:30806-30812.
42. Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, Poso A, Leppänen J, and Saario SM (2009) Screening of various hormone-sensitive lipase inhibitors as endocannabinoid- hydrolyzing enzyme inhibitors. ChemMed-Chem 4:1253-1259.
43. Mori K, Kim J, and Sasaki K (2011) Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides 32:246-252.
44. Muccioli GG, Labar G, and Lambert DM (2008) CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem 9:2704-2710.
45. 1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras. Neurosci Lett 506:111-115.
46. Savinainen JR, Saario SM, Niemi R, Järvinen T, and Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451-1459.
47. Savinainen JR, Yoshino M, Minkkilä A, Nevalainen T, and Laitinen JT (2010) Characterization of binding properties of monoglyceride lipase inhibitors by a versatile fluorescence-based technique. Anal Biochem 399:132-134.
48. Scammell TE and Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243-266.
49. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, and Brown HA (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 5:108-117.
50. Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, Ogawa T, et al. (2000) Pyrrolidine inhibitors of human cytosolic phospholipase A2. J Med Chem 43:1041-1044.
51. Seno K, Okuno T, Nishi K, Murakami Y, Yamada K, Nakamoto S, and Ono T (2001) Pyrrolidine inhibitors of human cytosolic phospholipase A2. 2. Synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone.' Bioorg Med Chem Lett 11:587-590.
52. Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis CE, Middlemiss DN, and Brown F (1999) Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 128:1-3.
53. Song H, Ramanadham S, Bao S, Hsu FF, and Turk J (2006) A bromoenol lactone suicide substrate inactivates group VIA phospholipase A2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. Biochemistry 45:1061-1073.
54. Soria-Gómez E, Matias I, Rueda-Orozco PE, Cisneros M, Petrosino S, Navarro L, Di Marzo V, and Prospéro-García O (2007) Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109-1116.
55. 2+ signalling: problems and pitfalls. Trends Pharmacol Sci 19:370-375.
56. Tsuboi K, Hilligsmann C, Vandevoorde S, Lambert DM, and Ueda N (2004) N-Cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J 379:99-106.
57. Turunen PM, Ekholm ME, Somerharju P, and Kukkonen JP (2010a) Arachidonic acid release mediated by OX1 orexin receptors. Br J Pharmacol 159:212-221.
58. Turunen PM, Putula J, and Kukkonen JP (2010b) Filtration assay for arachidonic acid release. Anal Biochem 407:233-236.
59. 1 receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem 286:37414-37428.
60. Zheng H, Corkern M, Stoyanova I, Patterson LM, Tian R, and Berthoud HR (2003) Peptides that regulate food intake: appetite-inducing accumbens manipulation activates hypothalamic orexin neurons and inhibits POMC neurons. Am J Physiol Regul Integr Comp Physiol 284:R1436-R1444.